Table 1.
CD6 co-stimulation with activated leucocyte-cell adhesion molecule (ALCAM) enhances preferentially the CD25 expression in CD3-activated human human peripheral blood mononuclear cells (PBMC) in vitro.
| Protein expression† |
||||
|---|---|---|---|---|
| CD marker | Condition* | Positive cells‡ | Molecules§ | Gene expression¶ |
| CD3 | CD3 | 1·12 | 0·93 | 1·59 |
| CD3/ALCAM | 1·12 | 0·96 | 1·48 | |
| CD4 | CD3 | 1·56 | 1·98 | 0·75 |
| CD3/ALCAM | 1·62 | 1·83 | 0·64 | |
| CD8 | CD3 | 1·63 | 1·21 | 2·19 |
| CD3/ALCAM | 1·72 | 1·15 | 2·13 | |
| CD6 | CD3 | 1·06 | 0·73 | 1·00 |
| CD3/ALCAM | 1·05 | 0·68 | 0·68 | |
| CD25 | CD3 | 4·86 | 7·75 | 9·31 |
| CD3/ALCAM | 4·89 | 12·73 | 14·46 | |
| CD69 | CD3 | 3·94 | 0·92 | 0·79 |
| CD3/ALCAM | 4·96 | 1·01 | 1·39 | |
Freshly isolated human PBMCs (3 × 104) were stimulated with the immobilized anti-CD3 monoclonal antibody (mAb) (0·25 µg/ml) alone or with ALCAM-Fc (1 µg/ml). Lymphocyte specific markers fold-expression compared to unstimulated cells is shown.
Difference at the protein level defined by flow cytometry.
Analysis of the percentage of labelled cells using specific conjugated mAb.
Definition of the surface molecules number defined by a bead-based receptor quantification analysis, as described in Materials and methods.
Difference at the gene transcription level defined by microarray analysis.